GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (TSX:NVCN) » Definitions » Profitability Rank

Neovasc (TSX:NVCN) Profitability Rank : 2 (As of Dec. 2022)


View and export this data going back to 2001. Start your Free Trial

What is Neovasc Profitability Rank?

Neovasc has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Neovasc's Operating Margin % for the quarter that ended in Dec. 2022 was -861.90%. As of today, Neovasc's Piotroski F-Score is 3.


Competitive Comparison of Neovasc's Profitability Rank

For the Medical Devices subindustry, Neovasc's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neovasc's Profitability Rank Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neovasc's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Neovasc's Profitability Rank falls into.



Neovasc Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Neovasc has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Neovasc's Operating Margin % for the quarter that ended in Dec. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=-17.014 / 1.974
=-861.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Neovasc has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Neovasc Inc operating margin has been in a 5-year decline. The average rate of decline per year is -7.1%.

4. Consistency of the profitability

5. Predictability Rank


Neovasc Profitability Rank Related Terms

Thank you for viewing the detailed overview of Neovasc's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Neovasc (TSX:NVCN) Business Description

Traded in Other Exchanges
N/A
Address
13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.

Neovasc (TSX:NVCN) Headlines

From GuruFocus

Neovasc Reducer Obtains U.S. Outpatient Reimbursement

By Value_Insider Value_Insider 11-08-2022

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

By GuruFocusNews GuruFocusNews 06-25-2022

Shockwave Medical to Acquire Neovasc

By Stock market mentor Stock market mentor 01-17-2023

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

By GuruFocusNews GuruFocusNews 06-05-2022

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

By GuruFocusNews GuruFocusNews 07-05-2022